As a key contributor within our Process Development and MSAT team, this hands-on and strategic leader will define and deliver advanced analytics, statistical modeling, and fit for purpose data infrastructure for real time monitoring of cell and gene therapy manufacturing processes, helping to drive the late-stage development of our first clinical stage autologous cell therapy program targeting solid tumors. As a member of our Process Development and MSAT team, you will be a vital part of a highly collaborative group working to unlock the promise of precision cell therapy for patients, starting with our lead program amsoki-cel (OBX-115), a novel engineered tumor-infiltrating lymphocyte (TIL) cell therapy that uses our proprietary cytoDRiVE platform.